Mariusz Popin’s Post

With the wrap up of AMCP 2024 in New Orleans, we are thrilled to observe how the conference themes aligned so deeply with Clinakos Inc.'s mission to better healthcare outcomes and patient care. The conference was a catalyst for progress and collaboration in advancing better therapies & patent outcomes, mirroring Clinakos' relentless pursuit of advancing healthcare. Throughout the conference, there were insightful presentations, especially from Satellite Symposia which tackled the use of bispecific antibodies in Non-Hodgkin’s Lymphoma, updates on Chronic Lymphocytic Leukemia management, keeping pace with new developments in Multiple Myeloma, novel therapies for metastatic breast cancer, and many more. These were supported by multiple biopharma companies including Bristol Myers Squibb, Takeda, Novartis, The Janssen Pharmaceutical Companies of Johnson & Johnson, Gilead Sciences, Sanofi, Regeneron, and others. Kudos to all who contributed to the success of this remarkable gathering, including the esteemed speakers, dedicated attendees, and valued partners. Together, let's shape a healthier future for all!  #pharmaceutical #pharmaceuticals 

Breast Cancer Key abstracts | ASCO 2024 As ASCO 2024 is approaching, major pharmaceutical firms such as AstraZeneca, Daiichi Sankyo US, Merck, Gilead Sciences, Eisai Co., Ltd., Pfizer, and more are poised to reveal the highly anticipated findings. Anticipated updates include safety and antitumor activity findings of BB-1701 in locally advanced/metastatic HER2-low expressing breast cancer, the initial outcomes of PF-07220060's Phase I/IIa study in patients with HR+/HER2− metastatic breast cancer, survival data from DESTINY-Breast03 in patients with HER2+ metastatic breast cancer, and further analyses of Phase III trial INAVO120 in patients with PIK3CA-mutated, HR+/HER2‑negative locally advanced/metastatic breast cancer. For more detailed insights, visit: https://lnkd.in/gezZPj3Q #ASCO2024 #PharmaUpdates #BreastCancerResearch #BB1701 #PF07220060 #DESTINYBreast03 #INAVO120 #HER2Positive #HRPositive #MetastaticCancer #ClinicalTrials #MedicalResearch #CancerSurvival #TreatmentOutcomes #DataAnalysis

🚀 Exciting News from SciTech Development! 🚀 We are thrilled to announce that SciTech Development has received an additional supply of the drug fenretinide, a key pharmaceutical ingredient in the company's ST-001 investigational drug product and drug pipeline, from the National Cancer Institute (NCI). The NCI’s provision of fenretinide will enable SciTech to treat over 300 patients and advance our Phase 1a and 1b trials for relapsed or refractory T-cell non-Hodgkin lymphoma across six locations in the US, as well as in other cancer indications. With this new supply, we’re accelerating our progress in developing innovative cancer therapies that bring hope to those facing difficult-to-treat cancers. Learn more about the trials here: https://lnkd.in/e_xHCnQa Read the release: https://lnkd.in/enydhZcH #CancerResearch #Biotechnology #ClinicalTrials #CancerTherapeutics #SciTechDevelopment #HealthcareInnovation

We are thrilled to announce that SciTech Development, Inc. has received an additional supply of fenretinide, a key pharmaceutical ingredient in our ST-001 investigational drug product and drug pipeline, from the National Cancer Institute (NCI). This critical provision enables SciTech to treat over 300 patients and accelerate the progress of their Phase 1a and 1b trials for relapsed or refractory T-cell non-Hodgkin lymphoma across six U.S. locations, as well as in other cancer indications. With this new supply, we’re taking a bold step forward in developing innovative cancer therapies that SciTech brings hope to those facing difficult-to-treat cancers. 🗓 Join Us for an Exclusive Opportunity: On Wednesday, October 9th at 1 PM EST, we are hosting SciTech’s CEO, Earle Holsapple III, for an insightful discussion on the latest developments. If you’d like to learn more or be a part of this event, send me a message and join us as we dive into the exciting future of SciTech’s cancer therapies. #SciTechDevelopment #CancerResearch #TCellLymphoma #Pharmaceuticals #Biotech #CancerInnovation #Investors #Phase1Trials #BiotechInnovation

Join the fight against ovarian cancer this March and beyond! 🌟 With our ‘boots-on-the-ground’ support from our Clinical Enrollment Managers, we are able to enhance the patient screening and randomization rates in ovarian cancer studies, enabling patients to have faster access to life-improving treatments. #ovariancancerawareness #MakingADifference #SupportAndEmpower #RaiseAwareness #ovariancancermonth #ovariancancercampaign #ovariancancer #campaign #awareness #patients #patientaccess #patientrecruitment #clinicaltrials #innovativetrials #clinicalresearch #pharmaindustry #pharma #pharmaceutical #awarenessmatters

Such a meaningful milestone to reach first-in-human after years of effort by GW inventors and our licensee. Another example of a serendipitous discovery that can impact healthcare. While studying cardiac effects, they observed dermatological improvements. The last invention in a long research career was the one that made it. Inventors, please don't give up, the next one may be the big one. #autm #techtransfer #innovation #GWresearch

"Ambitious" may not be strong enough of a word here if they intend to launch 20 new drugs within the next six years. For some context, AZ manufactures, markets, and/or distributes ~37 drugs in the US, so this would be a major leap forward. I suppose that "launch" can be interpreted in many ways 😁 . It remains unclear how they intend to get there by "maintaining" their current R&D trajectory and instead focusing on operational and productivity improvements. An aggressive M&A strategy could provide one strategic path, but isn't forecasted. Nonetheless, it still feels like a small win for the industry to see such an aggressive plan come out at such a struggling time for the life sciences. Fingers crossed for patients that AZ will be able to hit even 10% of this goal.

#CStone Announces #EuropeanCommission Approval of #Sugemalimab (#Cejemly®) as First-Line Treatment for Non-Small Cell Lung Cancer 🎯CStone Pharmaceuticals, announced that the European Commission (EC) has approved sugemalimab (Brand name: Cejemly®) in combination with platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small-cell lung cancer (NSCLC) with no sensitizing EGFR mutations, or ALK, ROS1 or RET genomic tumour aberrations. 🥇Sugemalimab has become the #first anti-PD-L1 monoclonal antibody (#mAb) approved in Europe in combination with chemotherapy as first-line treatment for both squamous and non-squamous #NSCLC, making CStone the first innovative biopharmaceutical company to successfully bring a China domestic anti-PD-L1 mAb to the international market. 📌CStone has entered into a strategic commercialization partnership with Ewopharma for sugemalimab in Central & Eastern Europe and Switzerland. Discussions for commercial partnerships in Western Europe, Latin America, the Middle East, Southeast Asia, etc., are progressing well and are expected to conclude soon.

Defence Therapeutics receives a no-objection letter from Health Canada | Santé Canada for a Phase I Trial of ACCUM-002 (AccuTOX) as an anti-cancer molecule in patients with melanoma. Defence Therapeutics Inc, a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that it received a No Objection Letter (“NOL”) from Health Canada for its Clinical Trial Study number ACCUM-002-01 entitled “A Phase I trial of Intratumoral Administration of ACCUM-002TM as a Monotherapy and in Combination with Opdualag in Patients with Unresectables, Stage IIIB and IV, Melanoma”. Sébastien Plouffe CEO Defence Therapeutics https://lnkd.in/eg5y2Q9B #health #cancer #cancertreatment #melanoma #healthcanada

Recently, Ascentage Pharma announced that five research progress updates on three of its key products have been selected for poster presentations at the 2024 European Hematology Association (EHA) Annual Meeting. The three products are Olverembatinib, APG-2575, and APG-5918. It is worth noting that four clinical studies on Ascentage Pharma's Olverembatinib, APG-2575, and APG-2449 have also been selected for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Additionally, during the 2024 American Association for Cancer Research (AACR) Annual Meeting held in April, clinical research progress on Olverembatinib, APG-115, APG-2449, and APG-5918 was showcased. For Ascentage Pharma, which has eight products at the clinical stage or beyond, having five products featured internationally in the first half of 2024 alone means that 62.5% of their clinical pipeline products have already gained international exposure. #APIs #Medical #Rawmaterials #Pharma #Medicine #Pharmaceutical